Trial · NCT00782067
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Overall Response Rate (ORR) | Midostaurin (PKC412) | 59.6 | 95% Confidence Interval 48.6 to 69.8 | Percentage of participants | |
| Median Time to Duration of Response (DoR) | Midostaurin (PKC412) | 31.4 | 95% Confidence Interval 10.8 to NA | Months | |
| Median Time to Response (TTR) | Midostaurin (PKC412) | 0.3 | Full Range 0.1 to 3.7 | Months | |
| Median Time to Progression-Free Survival (PFS) | Midostaurin (PKC412) | 17.0 | 95% Confidence Interval 10.2 to 24.8 | Months | |
| Median Time to Overall Survival (OS) | Midostaurin (PKC412) | Primary Efficacy Population (PEP) (n=89) | 26.8 | 95% Confidence Interval 17.6 to 34.4 | Months |
| Median Time to Overall Survival (OS) | Midostaurin (PKC412) | Full Analysis Set (FAS) (n=116) | 28.7 | 95% Confidence Interval 20.3 to 38.0 | Months |
| Long-term Safety and Tolerability of Midostaurin | Midostaurin (PKC412) | AEs by Primary System Organ Class (SOC) (n=116) | 100 | Percentage of participants | |
| Long-term Safety and Tolerability of Midostaurin | Midostaurin (PKC412) | SAEs by Primary System Organ Class (SOC) (n=88) | 75.9 | Percentage of participants | |
| Long-term Safety and Tolerability of Midostaurin | Midostaurin (PKC412) | Deaths by Primary System Organ Class (SOC) (n=25) | 21.6 | Percentage of participants | |
| Histopathologic Response | Midostaurin (PKC412) | >50% decrease in mast cell (MC) (n=41) | 46.1 | Percentage of participants | |
| Histopathologic Response | Midostaurin (PKC412) | >0-<=50% decrease in mast cell (MC) (n=19) | 21.3 | Percentage of participants | |
| Histopathologic Response | Midostaurin (PKC412) | >50% decrease in serum tryptase (n=52) | 58.4 | Percentage of participants | |
| Histopathologic Response | Midostaurin (PKC412) | >0-<=50% decrease in serum tryptase (n=25) | 28.1 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00782067/results